A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics

A Study On The Prediction of Neoadjuvant Efficacy And Heterogeneity For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07107815

Enrollment

250

Registered

2025-08-06

Start date

2025-03-15

Completion date

2028-12-31

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer, Adenocarcinoma

Keywords

rectal cancer, MR cytometry imaging, deep-radiomics, neoadjuvant therapy

Brief summary

This study employed MR cytometry imaging combined with deep-radiomic research methods to predict the heterogeneity of rectal cancer, and constructed a model to predict the sensitivity to neoadjuvant therapy and potential mechanisms, assisting clinicians in early identification of high-risk tumors and patients with treatment-susceptible rectal cancer, and selecting individualized treatment plans, thereby improving patient prognosis. To this end, the investigators need to collect the clinical diagnosis and treatment data of patients, surgical and biopsy pathological information, pre-treatment rectal MRI images and colonoscopy biopsy tissue sections, and follow up on the surgical pathological results and recurrence of patients. This study is a non-interventional diagnostic study, which does not interfere with the routine diagnosis and treatment of patients, does not affect any medical rights of patients, and does not increase any medical risks.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Newly diagnosed rectal adenocarcinoma without previous treatment * Complete radical surgery in the institute * Complete rectal MRI within 2 weeks before surgery

Exclusion criteria

* Concomitant malignancies or systemic disease * Inadequate MR image quality for analysis * Incomplete clinicopathological data * Loss of follow-up

Design outcomes

Primary

Measure	Time frame
Pathological complete response	One month after surgery
Pathological tumor regression grade	One month after surgery
progression-free survival	From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Secondary

Measure	Time frame
Pathological differentiation grade	One month after surgery

Countries

China

Outcome results